NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL

INTRODUCTION: The NovoTTF-100A System (NovoTTF™ Therapy, Optune®, Novocure Inc.) is approved for use as a combination therapy with adjuvant temozolomide after postoperative chemo-radiation for newly diagnosed supratentorial glioblastoma (GBM). In our experience, dermatologic adverse events (dAEs) du...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukai, Junya, Seki, Kohei, Sasaki, Takahiro, Koyama, Yoshiki, Nakao, Naoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719341/
http://dx.doi.org/10.1093/noajnl/vdac167.073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719341/
http://dx.doi.org/10.1093/noajnl/vdac167.073

Ejemplares similares